Bacterial vaccine shows promise as cancer immunotherapy
Columbia researchers have engineered probiotic bacteria that educate the immune system to destroy cancer cells, opening the door for a new class of cancer vaccines that take advantage of bacteria’s…
An AI-powered pipeline for personalized cancer vaccines
Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells and harnesses…
First phase of polio campaign concludes successfully in Gaza
Over 187 000 children under ten years of age were vaccinated with novel oral polio vaccine type 2 (nOPV2) in central Gaza during the first phase of a two-round polio…
COVID. A new treatment and vaccine for flu and various coronaviruses
A team of researchers, led by the University of Houston, has discovered two new ways of preventing and treating respiratory viruses. In back-to-back papers in Nature Communications, the team –…
New study highlights scale and impact of long COVID. The Lancet
In a new review paper, researchers from the Universities of Arizona, Oxford and Leeds analyzed dozens of previous studies into long COVID to examine the number and range of people…
Trust in physicians and hospitals declined over the course of the COVID-19 pandemic
A cross-representative survey of adults in the United States showed decreasing levels of trust in physicians and hospitals during the COVID-19 pandemic—and the lower the trust, the less likely an…
NIH-sponsored trial of nasal COVID-19 vaccine opens
A Phase 1 trial testing the safety of an experimental nasal vaccine that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19, is…
Risk reduction from HPV vaccination goes beyond cervical cancer #ASCO24
Results from a new study suggest that the human papillomavirus (HPV) vaccine is effective in preventing the development of several types of cancers caused by HPV, most particularly head and…
TG SALUTEDOMANI TV: VACCINE AND CANCERS, MICROPLASTICS, ELECTRONIC SKIN
ONE VACCINE, MANY CANCERS In a new study published in Blood Advances, researchers from the UChicago Pritzker School of Molecular Engineering’s Hubbell Lab created with a novel approach to develop…
Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen
Colorized scanning electron micrograph of mpox virus particles (blue) on the surface of infected VERO E6 cells (pink). NIAID A dose-sparing intradermal mpox vaccination regimen was safe and generated an…